Knockdown of RASD1 improves MASLD progression by inhibiting the PI3K/AKT/mTOR pathway.

ABSTRACT:

Background

There is still no reliable therapeutic targets and effective pharmacotherapy for metabolic dysfunction-associated steatotic liver disease (MASLD). RASD1 is short for Ras-related dexamethasone-induced 1, a pivotal factor in various metabolism processes of Human. However, the role of RASD1 remains poorly illustrated in MASLD. Therefore, we designed a study to elucidate how RASD1 could impact on MASLD as well as the mechanisms involved.

Methods

The expression level of RASD1 was validated in MASLD. Lipid metabolism and its underlying mechanism were investigated in hepatocytes and mice with either overexpression or knockdown of RASD1.

Results

Hepatic RASD1 expression was upregulated in MASLD. Lipid deposition was significantly reduced in RASD1-knockdown hepatocy

SUBMITTER: Zeng G 

PROVIDER: S-EPMC11681670 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature